IN FOCUS: Syngene International
Pharmaceutical Technology
APRIL 28, 2023
The company has been ranked in the Business Expansion and Research and Development categories in the Pharmaceutical Technology Excellence Rankings. The 10-year agreement is for manufacturing the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. until 2026.
Let's personalize your content